U.S. Markets closed

Lpath granted U.S., European patents related to ASONEP

Lpath received official notification from the European Patent Office, or EPO, and the U.S. Patent and Trademark Office, or USPTO, that the company has been issued three key patents. The patents cover methods of detecting sphingolipid levels, as well as covering monoclonal antibodies, including ASONEP and iSONEP, that bind to and neutralize sphingosine-1-phosphate.